GEMFIBROZIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Gemfibrozil, and what generic alternatives are available?
Gemfibrozil is a drug marketed by Mylan, Purepac Pharm, Apotex, Ascent Pharms Inc, Aurobindo Pharma Ltd, Cadila, Cadila Pharms Ltd, Caribe Holdings, Chartwell Molecules, Chartwell Rx, Hikma Pharms, Impax Pharms, Invagen Pharms, Northstar Hlthcare, Sun Pharm Inds Inc, Teva, and Watson Labs. and is included in twenty NDAs.
The generic ingredient in GEMFIBROZIL is gemfibrozil. Thirty-three suppliers are listed for this compound. Additional details are available on the gemfibrozil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gemfibrozil
A generic version of GEMFIBROZIL was approved as gemfibrozil by CHARTWELL MOLECULES on September 27th, 1993.
Summary for GEMFIBROZIL
US Patents: | 0 |
Applicants: | 17 |
NDAs: | 20 |
Finished Product Suppliers / Packagers: | 32 |
Raw Ingredient (Bulk) Api Vendors: | 135 |
Clinical Trials: | 41 |
Patent Applications: | 4,173 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for GEMFIBROZIL |
Drug Sales Revenues: | Drug sales revenues for GEMFIBROZIL |
What excipients (inactive ingredients) are in GEMFIBROZIL? | GEMFIBROZIL excipients list |
DailyMed Link: | GEMFIBROZIL at DailyMed |
Recent Clinical Trials for GEMFIBROZIL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
St. Louis University | Early Phase 1 |
Polaryx Therapeutics, Inc. | Phase 3 |
Bristol-Myers Squibb | Phase 1 |
Pharmacology for GEMFIBROZIL
Drug Class | Peroxisome Proliferator Receptor alpha Agonist |
Mechanism of Action | Peroxisome Proliferator-activated Receptor alpha Agonists |
Medical Subject Heading (MeSH) Categories for GEMFIBROZIL
Anatomical Therapeutic Chemical (ATC) Classes for GEMFIBROZIL
US Patents and Regulatory Information for GEMFIBROZIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan | GEMFIBROZIL | gemfibrozil | CAPSULE;ORAL | 073466-001 | Jan 25, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva | GEMFIBROZIL | gemfibrozil | TABLET;ORAL | 074256-001 | Oct 31, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cadila Pharms Ltd | GEMFIBROZIL | gemfibrozil | TABLET;ORAL | 203266-001 | Jun 17, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Ascent Pharms Inc | GEMFIBROZIL | gemfibrozil | TABLET;ORAL | 214603-001 | Jan 13, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |